In recent years, targeted therapies, such as ALK inhibitors and brentuximab vedotin (BV) have been developed, and they have demonstrated dramatic responses in chemoresistant ALK-positive ALCL [11,12,13]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.